BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2023-08-17 ms1000001079311439 来自贵州省

请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不

143 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2023-08-11 ms7000001902667042 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。

83 12

展开12条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2023-11-21 ms6000000198285398 来自贵州省

偏重的研究方向：microRNA
经验分享：稿件7186，润色提交，WB整膜三重复

84 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2023-04-28 ms8000000847274971 来自广东省

审稿速度:1.0 | 投稿命中率:75.0
偏重的研究方向：信号通路;基础研究
经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利

286 14

展开14条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-25 ms4000001640011867 来自福建省

偏重的研究方向：肿瘤
经验分享：24 年的 article 开始审了吗😂

23 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-24 ms6000001871307372 来自山东省

偏重的研究方向：分子生物学;肿瘤;生物化学
经验分享：请问这个有word模板吗

19 0

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-17 未知… 来自北京

偏重的研究方向：分子生物学;生物化学
经验分享：2023年11月28号投稿，至今仍然是submitted to Journal

23 7

展开7条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-19 1487c463m49暂无昵称来自重庆

刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。

20 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-16 ms6000000187674201 来自上海

审稿速度:1.0 | 投稿命中率:25.0
偏重的研究方向：干细胞
经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投

23 3

展开3条回复

[GetPortalCommentsPageByObjectIdResponse(id=2153304, encodeId=b34c21533047f, content=请教各位，under review 快三周了，时间一直在变，但状态没变，这是什么情况有小伙伴知道不, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=143, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8b215411313, createdName=ms1000001079311439, createdTime=Thu Aug 17 21:43:03 CST 2023, time=2023-08-17, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2152251, encodeId=57672152251aa, content=审稿速度:1.0 | 投稿命中率:75.0 经验分享：分享一下投稿经验：7.25号Submitted to journal，7.28 内审，8.3 送外审，可以在**中跟踪到有多少审稿人，也可以看到有没有审稿人返稿，目前8月11日还没有审稿人返稿，等待后续，投的article。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=83, replyNumber=12, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6faa8350887, createdName=ms7000001902667042, createdTime=Fri Aug 11 12:45:13 CST 2023, time=2023-08-11, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2170081, encodeId=a92721e00814e, content=偏重的研究方向：microRNA 经验分享：稿件7186，润色提交，WB整膜三重复, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=84, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd069039656, createdName=ms6000000198285398, createdTime=Tue Nov 21 21:51:38 CST 2023, time=2023-11-21, status=1, ipAttribution=贵州省), GetPortalCommentsPageByObjectIdResponse(id=2128869, encodeId=835a21288699a, content=审稿速度:1.0 | 投稿命中率:75.0 偏重的研究方向：信号通路;基础研究 经验分享：分享一下投稿经验：4.3号Submitted to journal，4.21 Under review，4.21 退回让减少一点字数，改完之后当天就重新Submitted 了，4.22 Under review，4.28 凌晨发邮件说accepted。我的稿号是1956，投的是细胞实验，投稿前已经修改过语言。分享好运，希望大家投稿顺利, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=286, replyNumber=14, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=38b85714469, createdName=ms8000000847274971, createdTime=Fri Apr 28 05:51:05 CST 2023, time=2023-04-28, status=1, ipAttribution=广东省), GetPortalCommentsPageByObjectIdResponse(id=2183856, encodeId=49f22183856f3, content=偏重的研究方向：肿瘤 经验分享：24 年的 article 开始审了吗😂, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ad59031879, createdName=ms4000001640011867, createdTime=Thu Jan 25 12:36:08 CST 2024, time=2024-01-25, status=1, ipAttribution=福建省), GetPortalCommentsPageByObjectIdResponse(id=2183685, encodeId=581521836856d, content=偏重的研究方向：分子生物学;肿瘤;生物化学 经验分享：请问这个有word模板吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=313a8312882, createdName=ms6000001871307372, createdTime=Wed Jan 24 15:19:20 CST 2024, time=2024-01-24, status=1, ipAttribution=山东省), GetPortalCommentsPageByObjectIdResponse(id=2182131, encodeId=cf602182131e5, content=偏重的研究方向：分子生物学;生物化学 经验分享：2023年11月28号投稿，至今仍然是submitted to Journal, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=7, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20231206/2dee05e08ca84fb09f8330013e8e418e/e2624ef6b4474dc8bf92c7e3eed5d474.jpg, createdBy=4de09089222, createdName=未知…, createdTime=Wed Jan 17 09:07:42 CST 2024, time=2024-01-17, status=1, ipAttribution=北京), GetPortalCommentsPageByObjectIdResponse(id=2182748, encodeId=c84f2182e48ff, content=刚被接收了，期刊很人性化，很考虑作者实际情况，给出的返修意见也是小修，速度很快。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=20, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200708/0427ac93ed3d4316a3996cd50311d196/b96b19761d7d41daab64a783a8e05c73.jpg, createdBy=70ac5307148, createdName=1487c463m49暂无昵称, createdTime=Fri Jan 19 23:15:58 CST 2024, time=2024-01-19, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2182010, encodeId=aac62182010da, content=审稿速度:1.0 | 投稿命中率:25.0 偏重的研究方向：干细胞 经验分享：2024.1.10号投稿当晚under review 2024.1.15晚拒稿建议转投bbr 这个期刊现在比较挑，比我同学前年中的一篇做得好很多，但拒的比较果决投稿比较困难，着急的话还是要慎投, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b5ca8184855, createdName=ms6000000187674201, createdTime=Tue Jan 16 17:28:27 CST 2024, time=2024-01-16, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2180705, encodeId=cf502180e0515, content=垃圾杂志，大修一次返回后被拒了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=23, replyNumber=3, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f6289002293, createdName=ms5000000431727886, createdTime=Thu Jan 11 09:40:56 CST 2024, time=2024-01-11, status=1, ipAttribution=云南省)]

2024-01-11 ms5000000431727886 来自云南省

垃圾杂志，大修一次返回后被拒了

23 3

展开3条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务